Beaconlight Capital LLC Acquires 13,134 Shares of TransMedics Group, Inc. $TMDX

Beaconlight Capital LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 44.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,478 shares of the company’s stock after acquiring an additional 13,134 shares during the period. TransMedics Group accounts for about 2.2% of Beaconlight Capital LLC’s holdings, making the stock its 14th biggest position. Beaconlight Capital LLC owned about 0.12% of TransMedics Group worth $4,223,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after buying an additional 322,353 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after acquiring an additional 2,903 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after purchasing an additional 223,409 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of TransMedics Group by 43.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock worth $69,338,000 after purchasing an additional 171,810 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on TMDX shares. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a report on Wednesday. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $134.50.

Insiders Place Their Bets

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Trading Up 1.6%

TransMedics Group stock opened at $72.26 on Friday. The firm has a 50 day moving average of $71.73 and a 200 day moving average of $102.84. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of 16.42 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. During the same quarter in the prior year, the business earned $0.70 EPS. The business’s quarterly revenue was up 21.2% compared to the same quarter last year. As a group, research analysts predict that TransMedics Group, Inc. will post 1.88 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.